NAFLD and COVID-19: a Pooled Analysis.
Sonali SachdevaHarshwardhan KhandaitJonathan KopelMark M AloysiusRupak DesaiHemant GoyalPublished in: SN comprehensive clinical medicine (2020)
The earliest evidence from China suggested that COVID-19 patients are even more vulnerable to succumbing from complications in the presence of a multimorbid status, including metabolic syndrome. Due to ongoing metabolic abnormalities, non-alcoholic fatty liver disease (NAFLD) appears to be a potential risk factor for contracting SARS-CoV-2 infection and developing related complications. This is because of the interplay of chronically active inflammatory pathways in NAFLD- and COVID-19-associated acute cytokine storm. The risk of severe disease could also be attributed to compromised liver function as a result of NAFLD. We systematically reviewed current literature to ascertain the relationship between NAFLD and severe COVID-19, independent of obesity, which is considered the major factor risk factor for both NAFLD and COVID-19. We found that NAFLD is a predictor of severe COVID-19, even after adjusting for the presence of obesity (OR 2.358; 95% CI: 1.902-2.923, p < 0.001).
Keyphrases
- sars cov
- coronavirus disease
- metabolic syndrome
- respiratory syndrome coronavirus
- insulin resistance
- type diabetes
- early onset
- weight loss
- drug induced
- systematic review
- risk factors
- weight gain
- cardiovascular disease
- oxidative stress
- intensive care unit
- uric acid
- high fat diet induced
- skeletal muscle
- climate change
- physical activity